5.25
前日終値:
$5.41
開ける:
$5.41
24時間の取引高:
486.69K
Relative Volume:
0.41
時価総額:
$839.43M
収益:
$62.04M
当期純損益:
$-533.34M
株価収益率:
-1.3393
EPS:
-3.92
ネットキャッシュフロー:
$-473.07M
1週間 パフォーマンス:
-15.42%
1か月 パフォーマンス:
-8.92%
6か月 パフォーマンス:
-45.73%
1年 パフォーマンス:
-45.50%
Vir Biotechnology Inc Stock (VIR) Company Profile
名前
Vir Biotechnology Inc
セクター
電話
415-906-4324
住所
1800 OWENS STREET, SAN FRANCISCO, CA
VIR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
VIR
Vir Biotechnology Inc
|
5.24 | 839.43M | 62.04M | -533.34M | -473.07M | -3.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
431.67 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
538.81 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
547.58 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
253.01 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
230.82 | 27.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-01-29 | ダウングレード | JP Morgan | Overweight → Neutral |
2023-09-08 | ダウングレード | BofA Securities | Buy → Neutral |
2023-03-06 | アップグレード | JP Morgan | Neutral → Overweight |
2023-02-21 | アップグレード | Goldman | Neutral → Buy |
2023-01-27 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
2022-09-14 | 開始されました | SVB Leerink | Outperform |
2022-09-09 | 開始されました | Morgan Stanley | Underweight |
2022-03-03 | アップグレード | Robert W. Baird | Underperform → Neutral |
2021-12-21 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2021-10-25 | アップグレード | JP Morgan | Underweight → Neutral |
2021-09-22 | ダウングレード | Goldman | Buy → Neutral |
2021-06-04 | 再開されました | Robert W. Baird | Neutral |
2021-01-27 | ダウングレード | JP Morgan | Neutral → Underweight |
2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-05 | 開始されました | BofA Securities | Buy |
2020-09-14 | アップグレード | Goldman | Neutral → Buy |
2020-09-11 | アップグレード | JP Morgan | Underweight → Neutral |
2020-08-20 | 開始されました | Needham | Buy |
2020-03-19 | ダウングレード | JP Morgan | Neutral → Underweight |
2020-03-13 | ダウングレード | Goldman | Buy → Neutral |
2020-02-27 | ダウングレード | Robert W. Baird | Neutral → Underperform |
2020-02-04 | ダウングレード | JP Morgan | Overweight → Neutral |
2019-11-14 | 開始されました | Robert W. Baird | Neutral |
2019-11-05 | 開始されました | Barclays | Overweight |
2019-11-05 | 開始されました | Cowen | Outperform |
2019-11-05 | 開始されました | Goldman | Buy |
2019-11-05 | 開始されました | JP Morgan | Overweight |
すべてを表示
Vir Biotechnology Inc (VIR) 最新ニュース
Vir Biotechnology (VIR) Reveals Promising Data in Hepatitis B Treatment - GuruFocus
Vir Biotechnology Presents Promising Phase 2 Hepatitis B Data - TipRanks
Vir Biotechnology, Inc. (NASDAQ:VIR) Q1 2025 Earnings Call Transcript - Insider Monkey
Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha
Vir Biotechnology’s Earnings Call: Mixed Sentiment Amid Progress - TipRanks
Vir Biotechnology (VIR) Unveils Promising Hepatitis B Treatment Data | VIR Stock News - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study | VIR Stock News - GuruFocus
Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - Business Wire
Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha
Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus - MSN
Vir Biotechnology Reports Q1 2025 Financial Results - TipRanks
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Advancements - GuruFocus
Vir Biotechnology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - BioSpace
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
Earnings call transcript: Vir Biotech Q1 2025 reports increased R&D expenses - Investing.com
Vir Biotechnology (VIR) Falls Short on Q1 Revenue, Advances Clinical Programs | VIR Stock News - GuruFocus
Vir Biotechnology Inc. (VIR) Misses Q1 EPS by 1c - StreetInsider
Vir Biotechnology Q1 2025 Earnings Preview - MSN
Earnings Outlook For Vir Biotechnology - Nasdaq
Vir Biotechnology Inc expected to post a loss of 84 cents a shareEarnings Preview - TradingView
(VIR) On The My Stocks Page - news.stocktradersdaily.com
BlackRock, Inc. Reduces Stake in Vir Biotechnology Inc. - GuruFocus
Will Vir Biotech's Hepatitis B And D Data Presentations Give The Stock A Much-Needed Boost? - RTTNews
Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - BioSpace
Vir Biotechnology SVP sells shares for $14,291 - MSN
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver Congress 2025 - marketscreener.com
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - BioSpace
Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 | VIR Stock News - GuruFocus
When (VIR) Moves Investors should Listen - news.stocktradersdaily.com
5 Analysts Have This To Say About Vir Biotechnology - Benzinga
Lobbying Update: $50,000 of VIR BIOTECHNOLOGY INC. lobbying was just disclosed - Nasdaq
New Mpro inhibitors revealed in Vir Biotechnology patent - BioWorld MedTech
Vir Biotechnology, Inc. (VIR): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock By Investing.com - Investing.com South Africa
Vir Biotechnology CEO Marianne de Backer sells $474,238 in stock - Investing.com
Vir Biotechnology CEO Sells Shares to Cover Tax Obligations - TradingView
Vir Biotechnology stock hits 52-week low at $6.07 By Investing.com - Investing.com Australia
Vir Biotechnology stock hits 52-week low at $6.07 - Investing.com
Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Vir Biotechnology Insiders Sell US$1.3m Of Stock, Possibly Signalling Caution - simplywall.st
Vir Biotechnology, Inc. (NASDAQ:VIR) is favoured by institutional owners who hold 53% of the company - Yahoo
Vir Biotechnology stock hits 52-week low at $6.54 By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week low at $6.54 - Investing.com India
(VIR) Trading Advice - news.stocktradersdaily.com
Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - Quantisnow
Brii Bio Secures 4-Year Cash Runway Despite Wider Losses: Key HBV Trial Success - Stock Titan
Hepatitis D Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com
(VIR) Trading Signals - Stock Traders Daily
Vir Biotechnology Inc (VIR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):